Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Session 5 – HER2 as a Target in Breast Cancer

Value/Health Economics of Testing and Targeting (Incl. MCBS, ESCAT Actionability, RWD)

Date

10 Jun 2023

Session

Session 5 – HER2 as a Target in Breast Cancer

Topics

Cancer Care Equity Principles and Health Economics; Genetic and Genomic Testing; Targeted Therapy

Tumour Site

Breast Cancer

Presenters

D. Trapani, IT

Resources

This content is available to ESMO members and event participants.

Login

Resources from the same session

10 Jun 2023

Update on the Clinical Treatment Algorithm in HER2 Positive Disease (Early and Metastatic)

Presenter: J. Cortés, ES

Session: Session 5 – HER2 as a Target in Breast Cancer

Resources:

Slides

Webcast

10 Jun 2023

HER2 Pathway: Testing HER2 Expression and HER2 Mutations

Presenter: A. Prat, ES

Session: Session 5 – HER2 as a Target in Breast Cancer

Resources:

Slides

Webcast

10 Jun 2023

HER2 Low Disease – Clinical Trials and Challenges in Testing

Presenter: G. Curigliano, IT

Session: Session 5 – HER2 as a Target in Breast Cancer

Resources:

Slides

Webcast